Research programme: anticancer antibiotics - Astellas Pharma

Drug Profile

Research programme: anticancer antibiotics - Astellas Pharma

Alternative Names: Thioviridamide

Latest Information Update: 05 Feb 2008

Price : $50

At a glance

  • Originator Astellas Pharma; University of Tokyo
  • Class Cyclic peptides
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Jun 2006 A clinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top